Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ASPH | Q12797 | 1/20 | 0.31 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32679735 | 0.78 | TRIM24 (0.35) | CCR1CCR5CCR8 | |
| SCHEMBL12468608 | 0.78 | CCR1 (0.35) | CCR1CCR5CCR8 | |
| SCHEMBL4789975 | 0.78 | TRIM24 (0.35) | CCR1CCR5CCR8 | |
| SCHEMBL28281345 | 0.78 | CCR1 (0.32) | CCR1CCR5CCR8NFE2L2 | |
| SCHEMBL29544937 | 0.78 | NFE2L2 (0.35) | CCR1CCR5CCR8NFE2L2 | |
| SCHEMBL25346137 | 0.78 | CCR1 (0.32) | CCR1CCR5CCR8NFE2L2 | |
| SCHEMBL14691566 | 0.78 | NFE2L2 (0.35) | CCR1CCR5CCR8NFE2L2 | |
| SCHEMBL30630531 | 0.75 | NFE2L2 (0.34) | CCR1CCR5CCR8NFE2L2 | |
| SCHEMBL14691512 | 0.75 | NFE2L2 (0.37) | CCR1CCR5CCR8NFE2L2 | |
| SCHEMBL1466874 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023150709-A2 | METHODS OF SYNTHESIZING DEUTERATED SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| WO-2017133667-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017133657-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-9334265-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2016-05-10 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2015-10-29 | — | — | US | disclosed |
| US-9000181-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2015-04-07 | — | — | US | disclosed |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8779153-B2 | 3-amino-pyrazole derivatives useful against tuberculosis | GLAXO GROUP LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| EP-2627653-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | Glaxo Group Limited (GB) | 2013-08-21 | — | — | EP | disclosed |
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| WO-2012049161-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203802-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | CCR1 234/4885CCR5 56/4885CCR8 714/4885 |
| US-20140288133-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | CCR1 179/4885CCR5 43/4885CCR8 524/4885 |
| US-20150307485-A1 | 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 | CCR1 216/4885CCR5 54/4885CCR8 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.